Viral load predicts new world health organization stage 3 and 4 events in HIV-infected children receiving highly active antiretroviral therapy, independent of CD4 T lymphocyte value

Clinical Infectious Diseases

Volumn 51, Issue 11, 2010, Pages 1325-1333

  Oliveira, Ricardo ^a   Krauss, Margot ^f   Essama Bibi, Suzanne ^f   Hofer, Cristina ^a   Harris, D Robert ^f   Tiraboschi, Adriana ^b   De Souza, Ricardo ^e   Marques, Heloisa ^b   Succi, Regina ^c   Abreu, Thalita ^a   Della Negra, Marinella ^d   Hazra, Rohan ^g   Mofenson, Lynne M ^g   Siberry, George K ^g  

^a FEDERAL UNIVERSITY OF RIO DE JANEIRO   (Brazil)

^b UNIVERSITY OF SÃO PAULO   (Brazil)

^c FEDERAL UNIVERSITY OF SÃO PAULO   (Brazil)

^d INSTITUTO DE INFECTOLOGIA EMÍLIO RIBAS   (Brazil)

^e UNIVERSITY OF CAXIAS DO SUL   (Brazil)

^f WESTAT   (United States)

^g EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH AND HUMAN DEVELOPMENT   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HEMOGLOBIN; NONNUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR; PROTEINASE INHIBITOR; RNA DIRECTED DNA POLYMERASE INHIBITOR;

ARTICLE; CD4+ T LYMPHOCYTE; CHILD; FEMALE; FOLLOW UP; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOLOGICAL PARAMETERS; LABORATORY TEST; MAJOR CLINICAL STUDY; MALE; PERINATAL INFECTION; PRESCHOOL CHILD; PRIORITY JOURNAL; SCHOOL CHILD; VIRUS LOAD; WORLD HEALTH ORGANIZATION;

EID: 78649885940     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1086/657119     Document Type: Article

References (28)

1. Working Group on Antiretroviral Therapy and Medical Management of HIV-Infected Children. Guidelines for the use of antiretroviral agents in pediatric HIV infection: February 23, 2009. http://aidsinfo.nih.gov/ ContentFiles/PediatricGuidelines.pdf. Accessed 22 March 2010.
2. Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents: December 1, 2009. http://www.aidsinfo.nih.gov/ContentFiles/AdultandAdolescentGL. pdf. Accessed 22 March 2010.
3. Mee P, Fielding KL, Charalambous S, Churchyard GJ, Grant AD. Evaluation of the WHO criteria for antiretroviral treatment failure among adults in South Africa. AIDS 2008; 22:1971-1977.
4. World Health Organization. Antiretroviral therapy of HIV infection in infants and children: towards universal access - recommendations for a public health approach. 2006. http://www.who.int/hiv/pub/guidelines/paediatric020907. pdf. Accessed 22 March 2010.
5. Shearer WT, Quinn TC, LaRussa P, et al; Women and Infants Transmission Study Group. Viral load and disease progression in infants infected with human immunodeficiency virus type 1. N Engl J Med 1997; 336(19):1337-1342.
6. Palumbo PE, Raskino C, Fiscus S, et al. Predictive value of quantitative plasma HIV RNA and CD4+ lymphocyte count in HIV-infected infants and children. JAMA 1998; 279(10):756-761.
7. Mofenson LM, Korelitz J, Meyer WA 3rd, et al; National Institute of Child Health and Human Development Intravenous Immunoglobulin Clinical Trial Study Group. The relationship between serum human immunodeficiency virus type 1 (HIV-1) RNA level, CD4 lymphocyte percent, and long-term mortality risk in HIV-1-infected children. J Infect Dis 1997; 175(5):1029-1038.
8. Hazra R, Stoszek SK, Freimanis-Hance L, et al. Cohort profile: NICHD International Site Development Initiative (NISDI) - a prospective, observational study of HIV-exposed and HIV-infected children at clinical sites in Latin American and Caribbean countries. Int J Epidemiol 2009; 38(5):1207-1214.
9. World Health Organization. WHO case definitions of HIV for surveillance and revised clinical staging and immunological classification of HIV-related disease in adults and children: August 7, 2006. http://www.womenchildrenhiv.org/ wchiv?pagepcharts-00-02. Accessed 22 October 2008.
10. World Health Organization. Antiretroviral therapy for HIV infection in children: towards universal access - recommendations for a public health approach, 2010 revision. 2010. http://www.who.int/hiv/pub/paediatric/ infants2010/en/index.html. Accessed 23 July 2010.
11. Gupta RK, Hill A, Sawyer AW, et al. Virological monitoring and resistance to first-line highly active antiretroviral therapy in adults infected with HIV-1 treated under WHO guidelines: a systematic review and meta-analysis. Lancet Infect Dis 2009; 9(7):409-417.
12. Calmy A, Ford N, Hirschel B, et al. HIV viral load monitoring in resource-limited regions: optional or necessary? Clin Infect Dis 2007; 44(1):128-134.
13. Brady MT, Oleske JM, Williams PL, et al; Pediatric AIDS Clinical Trials Group219/219C Team. Declines in mortality rates and changes in causes of death in HIV-1-infected children during the HAART era. J Acquir Immune Defic Syndr 2010; 53(1):86-94.
14. Sutcliffe CG, van Dijk JH, Bolton C, Persaud D, Moss WJ. Effectiveness of antiretroviral therapy among HIV-infected children in sub-Saharan Africa. Lancet Infect Dis 2008; 8(8):477-489. (Pubitemid 352005822)
15. Ciaranello AL, Chang Y, Margulis AV, et al. Effectiveness of pediatric antiretroviral therapy in resource-limited settings: a systematic review and meta-analysis. Clin Infect Dis 2009; 49(12):1915-1927.
16. Callens SF, Shabani N, Lusiama J, et al; SARA team. Mortality and associated factors after initiation of pediatric antiretroviral treatment in the Democratic Republic of the Congo. Pediatr Infect Dis J 2009;28(1):35-40.
17. Bolton-Moore C, Mubiana-Mbewe M, Cantrell RA, et al. Clinical outcomes and CD4 cell response in children receiving antiretroviral therapy at primary health care facilities in Zambia. JAMA 2007; 298(16):1888-1899.
18. Smith K, Kuhn L, Coovadia A, et al. Immune reconstitution inflammatory syndrome among HIV-infected South African infants initiating antiretroviral therapy. AIDS 2009; 23(9):1097-1107.
19. Bagchi S, Kempf MC, Westfall AO, et al. Can routine clinical markers be used longitudinally to monitor antiretroviral therapy success in resource-limited settings? Clin Infect Dis 2007; 44(1):135-138.
20. Moore DM, Awor A, Downing R, et al. CD4+ T-cell count monitoring does not accurately identify HIV-infected adults with virologic failure receiving antiretroviral therapy. J Acquir Immune Defic Syndr 2008; 49(5):477-484.
21. Vaz P, Chaix ML, Jani I, et al. Risk of extended viral resistance in human immunodeficiency virus-1-infected Mozambican children after first-line treatment failure. Pediatr Infect Dis J 2009;28(12):e283-e287.
22. Ferry T, Raffi F, Collin-Filleul F, et al; ANRS CO8 (APROCO-COPILOTE) Study Group. Uncontrolled viral replication as a risk factor for non-AIDS severe clinical events in HIV-infected patients on long-term antiretroviral therapy: APROCO/COPILOTE (ANRS CO8) cohort study. J Acquir Immune Defic Syndr 2009; 51(4):407-415.
23. Petersen ML, van der Laan MJ, Napravnik S, et al. Long-term consequences of the delay between virologic failure of highly active antiretroviral therapy and regimen modification. AIDS 2008; 22(16):2097-2106.
24. Lundgren JD, Mocroft A, Gatell JM, et al; EuroSIDA Study Group. A clinically prognostic scoring system for patients receiving highly active antiretroviral therapy: results from the EuroSIDA study. J Infect Dis 2002; 185(2):178-187. (Pubitemid 34056441)
25. Grabar S, Le Moing V, Goujard C, et al. Response to highly active antiretroviral therapy at 6 months and long-term disease progression in HIV-1 infection. J Acquir Immune Defic Syndr 2005; 39(3):284-292.
26. Stringer JS, Zulu I, Levy J, et al. Rapid scale-up of antiretroviral therapy at primary care sites in Zambia: feasibility and early outcomes. JAMA 2006; 296(7):782-793.
27. Cross Continents Collaboration for Kids (3Cs4kids) Analysis and Writing Committee. Markers for predicting mortality in untreated HIV-infected children in resource-limited settings: a meta-analysis. AIDS 2008; 22(1):97-105.
28. Johannessen A, Garrido C, Zahonero N, et al. Dried blood spots perform well in viral load monitoring of patients who receive antiretroviral treatment in rural Tanzania. Clin Infect Dis 2009; 49(6):976-981.